TY - JOUR T1 - Epidemiological model with anomalous kinetics - Early Stages of the Covid-19 pandemic JF - medRxiv DO - 10.1101/2020.06.24.20139287 SP - 2020.06.24.20139287 AU - Ugur Tirnakli AU - Constantino Tsallis Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/12/28/2020.06.24.20139287.abstract N2 - We generalize the phenomenological, law of mass action-like, SIR and SEIR epidemiological models to situations with anomalous kinetics. Specifically, the contagion and removal terms, normally linear in the fraction I of infecteds, are taken to depend on and , respectively. These dependencies can be understood as highly reduced effective descriptions of contagion via anomalous diffusion of susceptibles and infecteds in fractal geometries, and removal (i.e., recovery or death) via complex mechanisms leading to slowly decaying removal-time distributions. We obtain rather convincing fits to time series for both active cases and mortality with the same values of (qup, qdown) for a given country, suggesting that such aspects may in fact be present in the early evolution of the Covid-19 pandemics. We also obtain approximate values for the effective population Neff, which turns out to be a small percentage of the entire population N for each country.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No consent was necessary. All the data used in the manuscript are publicly available.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCovid-19 data is available here: https://data.humdata.org/dataset/novel-coronavirus-2019-ncov-cases ER -